46 citations
,
November 1995 in “The Journal of Dermatology” This study found that immunotherapy with DNCB or DPCP showed better therapeutic effects than intralesional triamcinolone acetonide for patients with bald areas greater than 50 cm², including alopecia totalis and universalis.
47 citations
,
September 1995 in “British Journal of Dermatology” This review discusses the complication of vitiligo in patients undergoing diphencyprone sensitization therapy for alopecia universalis and reports no new clinical findings.
41 citations
,
November 1993 in “Journal of The American Academy of Dermatology” This study found that DPCP treatment led to cosmetically acceptable hair regrowth in 38% of patients with chronic severe alopecia areata, while adding 5% minoxidil showed no significant clinical benefit.
84 citations
,
August 1991 in “British Journal of Dermatology” This study found that 67% of children treated with diphencyprone for alopecia areata or alopecia totalis regrew scalp hair, with 33% achieving complete regrowth.
36 citations
,
March 1989 in “British journal of dermatology/British journal of dermatology, Supplement” In this study, the authors compared topical diphencyprone and tretinoin gel for treating alopecia totalis and universalis, but the abstract does not report any definitive clinical results.
5 citations
,
July 1988 in “British journal of dermatology/British journal of dermatology, Supplement” Diphencyprone therapy can effectively treat severe hair loss in motivated patients.
55 citations
,
January 1988 in “Dermatology” This study observed that 6.7% of patients treated with diphencyprone for alopecia areata developed vitiligo, with varying patterns and improvements noted among cases.
42 citations
,
August 1987 in “Archives of Dermatology” In this study, 28.5% of patients with extensive alopecia areata had complete hair regrowth during treatment with squaric acid dibutylester, with outcomes linked to shorter alopecia duration and prompt dermatitis development.
122 citations
,
November 1984 in “Journal of the American Academy of Dermatology” This review discusses the potential autoimmune pathogenesis and various contributing factors of alopecia areata, noting that current treatments remain palliative while emerging therapies offer new hope for extensive cases.
14 citations
,
June 1982 in “Archives of Dermatology” This letter to the editor shares concerns about possible systemic effects from topical dinitrochlorobenzene therapy in a 25-year-old man treating alopecia areata.
50 citations
,
July 1981 in “Archives of Dermatology” This study found that applying dinitrochlorobenzene (DNCB), a contact allergen, led to hair regrowth in patients with alopecia areata, while croton oil did not have the same effect.